an independent news feed from Current Medicine Group™
- Latest oncology research
- Clinical trials
- Healthcare initiatives
- Practice guidelines
-
- Aug 26, 2010
- Urine protein test represents novel biomarker for prostate cancer UK researchers have identified a novel urinary biomarker for the detection of prostate cancer.
-
- Aug 26, 2010
- Careful patient selection for active surveillance reduces treatment need Prostate cancer patients are unlikely to require definitive treatment after undergoing active surveillance if they are selected on the basis of strict low-risk criteria, suggest US researchers.
-
- Aug 25, 2010
- Initial treatment choice influences overall cost of prostate cancer The financial costs of treatment for prostate cancer vary according to the initial treatment that patients receive, report researchers, who add that the impact lasts beyond the short-term costs.
-
- Aug 24, 2010
- Bcl-2 protein expression could indicate prostate resistance to radiotherapy Patients with prostate tumors that express the anti-apoptotic protein B-cell lymphoma 2 experience a shorter time to biochemical failure after radiotherapy compared with men whose tumors do not express the protein, study results show.
-
- Aug 24, 2010
- Prostate length predicts urinary problems after brachytherapy The length of a man’s prostate could help predict the likelihood of him experiencing urinary problems after receiving brachytherapy for prostate cancer, report researchers.
-
- Aug 23, 2010
- Familial prostate cancer risk influenced by screening awareness Men with first-degree relatives who have prostate cancer are more likely to undergo prostate-specific antigen screening than those with no family history, report researchers who believe that the finding may bias the results of genetic studies investigating familial prostate cancer risk.
-
- Aug 20, 2010
- PSA failure 5 years after prostate surgery linked to initial surgical outcomes Prostate cancer patients with an undetectable prostate-specific antigen level 5 years after surgery are more likely to experience late disease recurrence if they have a Gleason score of 7 or higher, extracapsular extension, or seminal vesicle invasion, study findings show.
-
- Aug 20, 2010
- Prostate cancer control improved by hypofractionated versus conventional RT Three-year rates of freedom from biochemical failure achieved after hypofractionated radiotherapy for prostate cancer are significantly better than those obtained after conventional fractionation radiotherapy, report researchers.
-
- Aug 19, 2010
- Acute toxicity predicts late injury after prostate radiotherapy A significant correlation exists between acute and late urinary and rectal injuries in prostate cancer patients treated with radiotherapy, indicate Italian study results.
-
- Aug 18, 2010
- HER-2 overexpression linked with worse prostate cancer outcomes Overexpression of the human epidermal growth factor receptor 2 gene may indicate worse clinical outcomes in prostate cancer patients, show the results of a meta-analysis.
Not signed in
Information
This is an AstraZeneca International website for healthcare professionals and is not intended for the following audiences who should use the links below.
Subscribe to RSS News Feed